Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors - A Southwest Oncology Group trial

Sarah A. Taylor, John Crowley, F. Stephen Vogel, Jeannette J. Townsend, Harmon J. Eyre, Kurt Jaeckle, Harry E. Hynes, Jerry T. Guy

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Twenty-three patients with malignant central nervous system tumors were treated with fludarabine phosphate (2-FAMP) on a 5 day bolus schedule. One brief partial response was observed in 20 malignant astrocytoma patients. 2FAMP as given in this protocol is inactive in previously treated patients with recurrent malignant astrocytomas.

Original languageEnglish (US)
Pages (from-to)195-197
Number of pages3
JournalInvestigational New Drugs
Volume9
Issue number2
DOIs
StatePublished - May 1 1991

Fingerprint

fludarabine phosphate
Central Nervous System Neoplasms
Astrocytoma
Appointments and Schedules

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Taylor, S. A., Crowley, J., Vogel, F. S., Townsend, J. J., Eyre, H. J., Jaeckle, K., ... Guy, J. T. (1991). Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors - A Southwest Oncology Group trial. Investigational New Drugs, 9(2), 195-197. https://doi.org/10.1007/BF00175089
Taylor, Sarah A. ; Crowley, John ; Vogel, F. Stephen ; Townsend, Jeannette J. ; Eyre, Harmon J. ; Jaeckle, Kurt ; Hynes, Harry E. ; Guy, Jerry T. / Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors - A Southwest Oncology Group trial. In: Investigational New Drugs. 1991 ; Vol. 9, No. 2. pp. 195-197.
@article{a5d2b965e9154eb19aac35b02a1ce5ac,
title = "Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors - A Southwest Oncology Group trial",
abstract = "Twenty-three patients with malignant central nervous system tumors were treated with fludarabine phosphate (2-FAMP) on a 5 day bolus schedule. One brief partial response was observed in 20 malignant astrocytoma patients. 2FAMP as given in this protocol is inactive in previously treated patients with recurrent malignant astrocytomas.",
author = "Taylor, {Sarah A.} and John Crowley and Vogel, {F. Stephen} and Townsend, {Jeannette J.} and Eyre, {Harmon J.} and Kurt Jaeckle and Hynes, {Harry E.} and Guy, {Jerry T.}",
year = "1991",
month = "5",
day = "1",
doi = "10.1007/BF00175089",
language = "English (US)",
volume = "9",
pages = "195--197",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

Taylor, SA, Crowley, J, Vogel, FS, Townsend, JJ, Eyre, HJ, Jaeckle, K, Hynes, HE & Guy, JT 1991, 'Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors - A Southwest Oncology Group trial', Investigational New Drugs, vol. 9, no. 2, pp. 195-197. https://doi.org/10.1007/BF00175089

Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors - A Southwest Oncology Group trial. / Taylor, Sarah A.; Crowley, John; Vogel, F. Stephen; Townsend, Jeannette J.; Eyre, Harmon J.; Jaeckle, Kurt; Hynes, Harry E.; Guy, Jerry T.

In: Investigational New Drugs, Vol. 9, No. 2, 01.05.1991, p. 195-197.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors - A Southwest Oncology Group trial

AU - Taylor, Sarah A.

AU - Crowley, John

AU - Vogel, F. Stephen

AU - Townsend, Jeannette J.

AU - Eyre, Harmon J.

AU - Jaeckle, Kurt

AU - Hynes, Harry E.

AU - Guy, Jerry T.

PY - 1991/5/1

Y1 - 1991/5/1

N2 - Twenty-three patients with malignant central nervous system tumors were treated with fludarabine phosphate (2-FAMP) on a 5 day bolus schedule. One brief partial response was observed in 20 malignant astrocytoma patients. 2FAMP as given in this protocol is inactive in previously treated patients with recurrent malignant astrocytomas.

AB - Twenty-three patients with malignant central nervous system tumors were treated with fludarabine phosphate (2-FAMP) on a 5 day bolus schedule. One brief partial response was observed in 20 malignant astrocytoma patients. 2FAMP as given in this protocol is inactive in previously treated patients with recurrent malignant astrocytomas.

UR - http://www.scopus.com/inward/record.url?scp=0025849697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025849697&partnerID=8YFLogxK

U2 - 10.1007/BF00175089

DO - 10.1007/BF00175089

M3 - Article

VL - 9

SP - 195

EP - 197

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -